Bispecific Antibody Market Advances as 180+ Companies Accelerate Clinical Development

Explore the FDA-approved bispecific antibody drugs and review bispecific antibody market dynamics - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Bispecific Antibody Market Dynamics and Challenges

Advances in antibody engineering, rising R&D investment, and expanding clinical pipelines are shaping the competitive landscape. Companies such as Roche, Regeneron, Genmab, and Zymeworks are developing technologies intended to improve antibody stability, manufacturing, and pharmacokinetic properties. Platforms such as knob-into-hole, CrossMab, and DuoBody support the design of different bispecific formats.

Nevertheless, manufacturing remains complex and expensive, particularly for molecules requiring precise assembly of distinct antibody components. Safety considerations, including cytokine release syndrome, off-target activity, and immunogenicity, can also complicate development. Biomarker identification and patient stratification are therefore important for optimizing treatment selection and managing potential adverse events.

To learn more about bispecific antibody development and production, visit Bispecific Antibody Production - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Developments in the Bispecific Antibody Domain

• In July 2025, Instil Bio announced US FDA clearance of an investigational new drug application for AXN-2510, a PD-L1 x VEGF bispecific antibody intended for a Phase I trial in relapsed or refractory solid tumors.
• In June 2025, Zai Lab reported preclinical findings for ZL-1503, an IL-13/IL-31R bispecific antibody designed to address inflammatory and itch-related pathways in atopic dermatitis. That month, BioNTech and Bristol Myers Squibb agreed to collaborate on the global development and commercialization of BNT327 across multiple solid tumors.
• In May 2025, Minghui Pharmaceutical announced the first-patient dosing in a Phase II study combining MHB039A, a PD-1 x VEGF bispecific antibody, with the TROP-2-targeting antibody-drug conjugate MHB036C in advanced NSCLC. Pfizer also entered an exclusive global licensing agreement, excluding China, with 3SBio for SSGJ-707, a PD-1 x VEGF bispecific antibody being evaluated in several cancer indications.
• In April 2025, the European Commission approved COLUMVI (glofitamab) with gemcitabine and oxaliplatin for specified adults with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem cell transplantation.
• Additional developments included a March 2025 patent grant in China for Ocean Biomedical's CHI3L1- and PD-1-targeting antibodies, first-patient dosing in a Phase I trial of CTIM-76 in March 2025, and preclinical presentation plans for Rondo Therapeutics' RNDO-564 in February 2025. In January 2025, Orion Corporation and Invenra announced a research collaboration using the B-Body platform, while Biocytogen and Acepodia announced a strategic collaboration involving dual-payload bispecific antibody-drug conjugates.

Scope of the Bispecific Antibody Competitive Landscape Report

The report provides global coverage of marketed therapies, pipeline candidates, and competitive developments. Key companies include Instil Bio, Akeso Biopharma, Janssen, Amgen, Roche, IGM Biosciences, MacroGenics, Regeneron Pharmaceuticals, Boehringer Ingelheim, ABL Bio, Compass Therapeutics, EpimAb Biotherapeutics, Affimed Therapeutics, Novo Nordisk, and others.

Featured candidates include AXN-2510, AK-104, amivantamab, blinatumomab, ivonescimab, zanidatamab, glofitamab, MGD024, KN-046, SI-B001, REGN-5458, CTX-8371, MCLA-129, AFM13, and Mim8.

Conclusion

The bispecific antibody landscape continues to evolve as researchers explore dual-targeting approaches across oncology, autoimmune diseases, and other therapeutic areas. With more than 180 companies investigating over 250 candidates, the pipeline offers substantial opportunities for innovation while presenting challenges involving manufacturing, safety, and clinical validation. Continued research, regulatory progress, and strategic partnerships will influence the future development and commercial potential of these therapies.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com